

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Conant Optical Co., Ltd.**  
**上海康耐特光學科技集團股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2276)**

**VOLUNTARY ANNOUNCEMENT**  
**2026 H-SHARE REPURCHASE PLAN**

Reference is made to: (i) the circular for the annual general meeting of Shanghai Conant Optical Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively referred to as the “**Group**”) dated 28 April 2025 (the “**2025 AGM Circular**”); and (ii) the Company’s poll results announcement dated 12 June 2025. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2025 AGM Circular.

On 12 June 2025, the Company held its 2024 Annual General Meeting, at which a resolution to grant the Board a general mandate to repurchase H-shares (the “**General Mandate**”) was considered and approved.

At the 12th meeting of the second session of the Board held on 7 April 2026, the Board considered and approved the “Proposal Regarding the 2026 H-Share Repurchase Plan”. To further safeguard the interests of shareholders and enhance investor confidence, pursuant to (i) the General Mandate, and (ii) the proposed general mandate to be granted to the Board to repurchase H-shares (subject to approval by the Company’s shareholders (“**Shareholders**”) at the forthcoming 2025 Annual General Meeting which is scheduled to be held in June 2026) (“**New Mandate**”), the Board has approved an H-share repurchase plan with a total repurchase amount not exceeding HK\$400 million (the “**H-share Repurchase Plan**”), the specific details of which are as follows:

## **PURPOSE AND USE OF THE H-SHARE REPURCHASE PLAN**

Based on our firm confidence in the Company's future prospects and our strong belief in the Company's value, and in order to further protect Shareholders' interests and enhance investor confidence, the Company intends to repurchase its H-shares after comprehensively considering its business prospects, operating performance, financial condition, future profitability, and the recent performance of the Company's H-shares in the secondary market.

## **TOTAL AMOUNT OF FUNDS AND SOURCES OF FUNDS TO BE USED FOR THE H-SHARE REPURCHASE PLAN**

The total amount of funds to be used for the H-Share Repurchase Plan will not exceed HK\$400 million. The share repurchase program will be financed by the Company's internal cash, and other funds permitted under applicable laws and regulations. If the repurchase is funded by the cash held in onshore accounts, the Company will arrange for the funds to be transferred overseas through foreign exchange purchases, and can only be finalized after obtaining approval from the State Administration of Foreign Exchange.

## **REPURCHASE PRICE**

Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"), the daily repurchase price of H-shares shall not exceed 5% or more of the average closing price of the H-shares over the five trading days immediately preceding the repurchase date, the specific price will depend on prevailing market conditions.

## **NUMBER OF H-SHARES TO BE REPURCHASED**

The number of H-Shares to be repurchased shall not exceed 10% of the total number of issued H-Shares of the Company (excluding treasury H-Shares) as of the date of approval of the General Mandate. The number of H-shares that may be repurchased under the New Mandate (assuming it is approved at the forthcoming 2025 Annual General Meeting) will depend on the number of issued H-shares on the date of the New Mandate.

The Board do not intend to exercise the General Mandate to the extent that the number of shares held by the public falls below the minimum percentage required by the Stock Exchange, or to the extent that it would result in an obligation to make a mandatory general offer to the Shareholders pursuant to Rules 26 and 32 of the Takeovers Code. Based on the above considerations, the number of H-shares to be repurchased under the Repurchase Plan is not expected to exceed 20,230,616 shares.

## **TERM OF THE H-SHARE REPURCHASE PLAN**

The term of the H-Share Repurchase Plan shall be 3 months from the date the Board considers and passes the Repurchase Plan. The repurchase term shall expire early if any of the following events occurs:

- 1) If the total amount of funds used under the H-Share Repurchase Plan reaches the maximum limit, the H-Share Repurchase Plan shall be deemed completed, and the repurchase term shall expire early as of that date;
- 2) If the Board resolves to terminate the H-Share Repurchase Plan prior to its expiration date, the repurchase term shall terminate early as of the date the Board passes such resolution;
- 3) Upon the expiration of the General Mandate, if the New Mandate is approved at the 2025 Annual General Meeting, the repurchase term shall be extended until 7 July 2026.

After the expiration of the term, the Company may still consider other repurchase plans based on corporate strategies and prevailing market conditions.

## **ARRANGEMENTS FOLLOWING THE REPURCHASE OF H-SHARES**

The H-shares repurchased under the H-Share Repurchase Plan will be held as treasury shares and disposed of in accordance with the Hong Kong Listing Rules, the Company's Articles of Association, and any subsequent authorizations required. Specifically, the Company will transfer (including by sale on the secondary market) or cancel such repurchased shares within three years after the completion of the repurchase under the H-Share Repurchase Plan and the publication of the repurchase result announcement.

Should the Company intend to cancel the repurchased shares in the future, it will strictly comply with the relevant decision-making and announcement procedures regarding capital reduction as stipulated in the Company Law of the People's Republic of China, the Company's Articles of Association, and other applicable laws, regulations, or stock exchange listing rules.

## **SPECIFIC AUTHORIZATION TO THE MANAGEMENT TO HANDLE MATTERS RELATED TO THE H-SHARE REPURCHASE PLAN**

To ensure the smooth implementation of the H-Share Repurchase Plan, the Board authorizes the Company's management to handle matters related to the share repurchase, including but not limited to, determining at its discretion during the repurchase term and in accordance with the Repurchase Plan, the timing, price, and quantity of shares to be repurchased, as well as handling other matters related to the share repurchase.

The foregoing authorization shall take effect from the date of its approval by the Board and shall remain in effect until the matters covered by such authorization have been fully completed.

## **RISK REMINDERS REGARDING THE SHARE REPURCHASE PLAN**

Shareholders and potential investors of the Company are advised that the H-share repurchase will be subject to market conditions and must comply with applicable laws and regulations, and that the New Mandate is subject to approval by the Shareholders via an ordinary resolution at the Company's 2025 Annual General Meeting to be convened. Pursuant to the Board's authorization, the Company will make repurchase decisions and implement them at its discretion during the repurchase term. The Company does not guarantee the timing, quantity, or price of any H-share repurchases. Shareholders and potential investors are advised to exercise caution when trading the Company's securities.

By order of the Board  
**Shanghai Conant Optical Co., Ltd.**  
**Fei Zhengxiang**

*Executive Director and Chairman of the Board*

Hong Kong, 8 April 2026

*As at the date of this announcement, the Board comprises Mr. Fei Zhengxiang, Mr. Zheng Yuhong, Mr. Xia Guoping, Mr. Chen Junhua, Mr. Wang Chuanbao and Ms. Cao Xue as executive Directors; Ms. Zhao Xiaoyun and Mr. Tian Kehan as non-executive Directors; and Dr. Xiao Fei, Mr. Chen Yi, Dr. Wu Ying and Mr. Jin Yiting as independent non-executive Directors.*